MD&DI

12/16/2025

🚀 Stereotaxis: Carving a Niche in the Competitive Surgical Robotics Market 🤖

In this clip from the latest episode of the Let’s Talk Medtech podcast, David Leo Fischel, CEO of Stereotaxis, talks about the company’s innovative approach to surgical robotics. 🎙️

Stereotaxis is making waves in the crowded surgical robotics space by focusing on precision, safety, and advancing the field of interventional medicine.

In this insightful conversation, Fischel shares how the company is leveraging its unique technology to stand out and deliver meaningful solutions for patients and clinicians alike.

💡 Curious about how Stereotaxis is navigating this competitive landscape? Check out the podcast clip and discover how they’re redefining the future of robotic surgery.

🎧 A link to the full episode here: https://www.youtube.com/watch?v=GSOS-pMbeO0

12/15/2025

The Future of Medtech Jobs: What to Expect in 2026 🌟

The medtech job market is undergoing a seismic shift, and by 2026, the landscape will look vastly different. In her latest article, MD+DI writer Claire Wallace explores the key factors driving this transformation, including federal layoffs, the rapid adoption of AI, and increased M&A activity.

One of the most striking insights? Versatility will be the name of the game. As John Crombie, president of Upstart Product Development, points out, the skills that once guaranteed success in medtech are evolving. For example, while mechanical engineers were once in high demand, the future belongs to professionals like biomedical engineers who bring adaptability and a broader skill set to the table.

This shift underscores the importance of staying ahead of industry trends and continuously upskilling to meet the demands of a rapidly changing market.

🔗 Read the full article to learn more about the future of medtech jobs and how you can prepare: https://bit.ly/4akd2U0

What are your thoughts on the evolving medtech job market? Let us know in the comments! 👇

The medtech job market faces major shifts in 2026 due to federal layoffs, AI adoption, and M&A activity. Versatile skills will be the key to success.

12/12/2025

Costa Rica is emerging as a key destination for medical device manufacturing. In this short video, MD+DI Senior Writer Claire Wallace discusses what this growing trend means for the industry with Amanda Pedersen and Omar Ford.

12/11/2025

Each year, the medical device industry has highs and lows. And each year, MD+DI editors take a hard look at the companies, market segments, and trends that stand out as the biggest winners and biggest losers for the industry.

We previously published our list of Medtech's 10 Biggest Winners (https://bit.ly/4q1XgRY). Now we're looking at the other side of the coin, the biggest losers. Check out the list below. https://bit.ly/48Av6rH

These companies, business moves, and market segments stood out this year as medtech's biggest losses.

12/11/2025

Big news! Our editors have crowned Medtronic the 2025 Medtech Company of the Year for setting the industry standard in supply chain resilience amid a high-stakes trade environment. 🏆

Discover the strategies behind their success and what it means for the future of medtech. Read the full story for more.

MD+DI editors name Medtronic as 2025 Medtech Company of the Year.

12/10/2025

Navigating through adversity is never easy, but it often leads to the most transformative journeys.

In this clip from the most recent episode of Let's Talk Medtech, David Leo Fischel, CEO of Stereotaxis, shares how the surgical robotics company faced a critical moment in its history—strong clinical data and a solid product, yet burdened by heavy debt and on the brink of bankruptcy.

Through strategic leadership and a clear vision, Fischel helped steer the company back on track, proving that resilience and innovation can overcome even the toughest challenges.

This story serves as a powerful reminder that, with the right mindset and determination, organizations can overcome obstacles and thrive. Watch the full episode of Let's Talk Medtech here: https://www.youtube.com/watch?v=GSOS-pMbeO0

12/08/2025

🏆 Big news! FastWave Medical has been crowned MD+DI’s Company of the Year—earning 206 out of 320 reader votes. The Brooklyn Park, MN team specializes in intravascular lithotripsy (IVL) technologies.

Don’t miss MD+DI’s interview with CEO and co-founder Scott Nelson as he reflects on the honor and teases what’s coming in 2026 for this fast-rising startup.

The medtech startup competes against larger players in the intravascular lithotripsy space, which include Johnson & Johnson and Boston Scientific.

12/05/2025

MD+DI recently featured an insightful interview with Adam Hesse, CEO of Full Spectrum, where he shared his perspective on the transformative trends shaping the medtech industry.

From the growing role of AI in FDA submissions to the rise of consumer-driven healthcare products and the challenges of marketing advanced remote patient monitoring tools directly to consumers, Adam provides a comprehensive look at the forces driving change in healthcare.

One key takeaway? The disruptive potential of AI implementation. Hesse emphasizes how AI is poised to impact every aspect of healthcare innovation and delivery, but he also underscores the critical need for human oversight to ensure its effective and ethical use.

As we look ahead to 2026, these trends will continue to redefine the medtech landscape, challenging organizations to adapt and innovate.

📖 Read the full article on MD+DI to dive deeper into Adam’s insights: https://bit.ly/4iGiBhz

Adam Hesse, CEO of Full Spectrum, discusses the transformative trends shaping the medtech industry.

12/03/2025

As the calendar year draws to a close, MD+DI recently convened a roundtable of subject matter experts (SMEs) to explore how global tariffs continue to shape medtech production and delivery.

This two-part series, authored by Joe Darrah, delves into the challenges and strategies medtech companies are employing to adapt to these economic pressures.

In Part One, we hear from a diverse group of industry leaders who share their perspectives on the impact of tariffs on design, production costs, and supply chain resilience:

Omar Al-Midani, Co-founder and CEO at PureWay, highlights how tariffs have driven up costs for everyday medical items like gloves and masks, leading companies to shift sourcing to lower-tariff regions in Asia.

Scott Nelson, Co-founder and CEO at FastWave Medical, emphasizes how tariffs have accelerated the push for resilient, domestically centered supply chains, positioning medtech as a model for American reindustrialization.

April Chan-Tsui, Director of Product Operations and Medtech Insights at Clarivate, discusses how increased costs for critical inputs have led to reassessments of R&D budgets and extended innovation timelines.

Christine Kachinsky-Bye, National Tax Sectors Leader and Life Sciences Tax Industry Leader at KPMG US, explains how escalating tariffs have disrupted cost structures, forcing companies to rethink supply chain strategies and materials used in device design.

Lynlee Brown, Global Trade Partner at EY, sheds light on how companies are leveraging trade agreements like the US-Mexico-Canada Free Trade Agreement to mitigate costs and adapt their design and R&D activities.

John Danes, President at Kent Elastomer Products, Inc. Products, shares how his company has managed to avoid significant tariff impacts by sourcing domestically or using tariff-exempt materials, though some price increases have been unavoidable.

This insightful discussion underscores the resilience and adaptability of the medtech industry in the face of global economic challenges.

📖 Read the full article here to learn more about how these leaders are navigating the complexities of tariffs: https://bit.ly/3XymGus

Stay tuned for Part Two, where we’ll dive deeper into the strategies and solutions shaping the future of medtech amidst ongoing tariff challenges.

MD+DI convened a roundtable of medtech industry experts to explore the ongoing impact of global tariffs.

12/02/2025

Surgical robotics is revolutionizing healthcare, transforming the way surgeries are performed and improving patient outcomes. In this rapidly growing space, Stereotaxis is carving out its niche alongside industry giants like Intuitive Surgical, Johnson & Johnson, and Medtronic.

David Leo Fischel, Chairman and CEO of Stereotaxis, joins the latest episode of Let’s Talk Medtech to share the company’s inspiring journey from survival to success. Based in St. Louis, MO, Stereotaxis recently secured $50 million in funding and has forged strong collaborations with NVIDIA, positioning itself as a key player in the future of surgical robotics.

In this episode, Fischel dives into Stereotaxis’ strategic vision and offers his perspective on the exciting advancements shaping the surgical robotics landscape.

View the full episode at the link to learn more about Stereotaxis’ innovative approach and the future of this transformative field. https://bit.ly/3Y0fzLt

In this episode, we’re joined by Stereotaxis CEO David Fischel, who shares the remarkable story of his company’s journey. Discover how Stereotaxis is revolut...

12/02/2025

Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured in the US after some continuous glucose monitoring (CGM) sensors have been potentially linked to 736 severe adverse events and seven deaths globally.

Here's what to do if you use Libre 3 or Libre 3 Plus sensors. https://utm.io/ujpgl

12/01/2025

Being a public company has its advantages, according to Lishan Aklog, MD, CEO of PAVmed Inc. In this clip from the latest episode of Let’s Talk Medtech, Dr. Aklog shares how PavMed’s public status enabled it to take advantage of the Lucid Diagnostics opportunities.

Catch the full episode right here: https://youtu.be/gz799CgrmGU